VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021

Apr 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-04-27

Reporting Person: Sachdev Amit (EVP, Chief Patient Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-27	Common Stock	M	3884	$86.52	Acquired	44017	Direct
2021-04-27	Common Stock	S	2346	$215.58	Disposed	41671	Direct
2021-04-27	Common Stock	S	1338	$216.67	Disposed	40333	Direct
2021-04-27	Common Stock	S	200	$217.69	Disposed	40133	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-27	Stock Option (Right to Buy)	$86.52	M	3884	Disposed	2027-02-02	Common Stock (3884)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	882	Indirect
Common Stock	7368	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $215.58 (range $215.09 to $216.07).

F3: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $216.67 (range $216.19 to $217.18).

F5: Open market sales reported on this line occurred at a weighted average price of $217.69 (range $217.60 to $217.78).

F6: Fully vested.